| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 551 | 7.339 | 7.503 | 11.624 | 14.224 | 17.933 | 21.987 |
| Total Income - EUR | - | - | - | 551 | 7.339 | 9.504 | 11.545 | 14.224 | 17.933 | 21.987 |
| Total Expenses - EUR | - | - | - | 322 | 3.217 | 2.719 | 2.381 | 9.731 | 16.930 | 20.815 |
| Gross Profit/Loss - EUR | - | - | - | 228 | 4.122 | 6.786 | 9.164 | 4.493 | 1.003 | 1.172 |
| Net Profit/Loss - EUR | - | - | - | 212 | 3.902 | 6.561 | 8.892 | 4.130 | 439 | 375 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Neuroand S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 1.376 | 1.109 | 3.326 | 2.752 | 56.765 | 55.869 |
| Current Assets | - | - | - | 594 | 2.829 | 4.795 | 10.957 | 15.701 | 19.035 | 19.605 |
| Inventories | - | - | - | 0 | 955 | 0 | 0 | 0 | 6.656 | 5.517 |
| Receivables | - | - | - | 35 | 530 | 456 | 920 | 3.970 | 9.201 | 14.048 |
| Cash | - | - | - | 559 | 1.344 | 4.339 | 10.037 | 11.731 | 3.177 | 41 |
| Shareholders Funds | - | - | - | 255 | 4.152 | 5.465 | 14.236 | 18.410 | 15.154 | 15.445 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 339 | 54 | 438 | 47 | 42 | 60.646 | 60.029 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neuroand S.r.l.